By Application: T2DM dominates, Obesity growing fastest Type 2 Diabetes Mellitus maintained the dominant application position in the GLP-1 Receptor Agonist Market in 2025, driven by the large established prescriber base, comprehensive insurance coverage for diabetes indications, and the longer clinical history of GLP-1 therapy in diabetes management that has built physician comfort and treatment guideline endorsement
In fact, a 2024 joint scientific statement from the American College of Lifestyle Medicine and several partner organisations identifies inadequate nutrient intake as a key nutritional risk for people taking GLP-1 medications
Muscle tissue burns roughly three times more calories at rest than fat tissue, meaning that preserving muscle during weight loss helps maintain metabolic rate and reduces the likelihood of weight regain
baseline) (STEP 1 trial extension)

The FDA has approved Dupixent to treat the following nine conditions: Moderate to severe eczema: Approved for moderate to severe chronic atopic dermatitis Asthma: Approved as an add-on maintenance treatment for uncontrolled moderate-to-severe eosinophilic or oral steroid-dependent asthma Chronic obstructive pulmonary disease (COPD): Approved as an additional treatment for inadequately controlled COPD with high blood eosinophils Chronic rhinosinusitis with nasal polyps (CRSwNP) : Approved as an add-on maintenance treatment for uncontrolled nasal polyps Eosinophilic esophagitis (EOE): Approved to treat an inflamed esophagus caused by too many white blood cells Chronic spontaneous urticaria (CSU): Approved for treatment of hives not controlled by H1 antihistamines Bullous pemphigoid (BP): Approved to treat a skin condition that causes itchy, fluid-filled blisters Prurigo nodularis (PN): Approved to treat a skin condition that causes severe itching Allergic fungal rhinosinusitis (AFRS): Approved to treat some nasal symptoms and inflammation Dupixent changes how your immune system works, with the goal of preventing your body from reacting to substances that are not an actual threat
